W
bioLLM/wiki

AI-Curated Biotech/Medical Knowledge Base
Live
Back to List View Graph View

Monoclonal antibody

A monoclonal antibody (mAb) is an antibody preparation derived from a single B-cell clone or engineered to recognize one defined antigenic determinant with high specificity.

1 paper landed today · 3 Nov 2026
  • Monoclonal Antibody Coformulations Reveal Three Interaction Patterns Governing Stability. PMID 42969742

Where the papers sit

28 papers from the last 6 months study monoclonal antibody directly

Study type 4 clinical trials · 1 observational · 4 human data · 18 preclinical · 1 unclassified

Themes one subject · 1 paradigm shift · 1 new direction

Those 28 are all about one subject.

  • Therapeutic Antibody Development

    Therapeutic antibody development spans formulation stability, aggregation measurement, delivery, pharmacokinetic modelling, antibody design, and clinical implementation. Recent efforts emphasize better analytical and manufacturing tools, including mass photometry, optimized pipetting, spray-freeze-dried inhalable powders, and sequence-based design. Translation also extends to subcutaneous administration, antibody-drug conjugates, antiviral combinations, allergy, cancer, infection, and vaccine-related care. No single biological mechanism or clinical direction unifies the set; its common focus is improving antibody therapies from design through use.

    28 papers

PARADIGM SHIFT

Combining monoclonal antibodies cannot be presumed to produce compatible formulations or therapeutic synergy

The coformulation study of ten IgG1 monoclonal antibodies and their binary mixtures 42969742Nov and the human cytomegalovirus neutralizing-antibody combination study 42684896Sep independently found that antibody combinations behave unpredictably rather than uniformly improving performance. Coformulation produced minimal, attractive, or repulsive interactions, with high-viscosity antibodies sometimes becoming either less or more viscous and diffusion measurements failing to predict viscosity consistently; antiviral combinations were mostly additive or antagonistic, with apparent synergy concentrated at saturating concentrations and varying by screening method. Combining antibodies therefore requires direct, context-specific testing of both physical compatibility and biological interaction rather than an assumption of additive benefit.

NEW DIRECTION

A monoclonal antibody can function as an antibiotic-resistance–reversal adjunct rather than as a standalone antimicrobial

The global epidemic carbapenem-resistant Acinetobacter baumannii model treated C32 as a neutralizing antibody against the extracellular resistance enzyme OXA23, and found that it inhibited carbapenem hydrolysis, lowered meropenem MICs in a co-culture model, and restored carbapenem susceptibility 42376991Jun. This gives the antibody a role not otherwise represented in the set: disabling a pathogen’s resistance mechanism to re-enable an existing antibiotic, rather than directly killing the pathogen, delivering a cytotoxic payload, or serving as a conventional antiviral, anti-inflammatory, or diagnostic binder.

Papers

The 28 papers from the last 6 months that study monoclonal antibody directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Therapeutic Antibody Development (28)
  1. Monoclonal Antibody Coformulations Reveal Three Interaction Patterns Governing Stability. Molecular pharmaceutics · 2 Nov 2026 PMID 42969742
  2. Predictors of Antiamyloid Medication Utilization and Adherence Among People With Alzheimer Disease and Mild Cognitive Impairment. Neurology · 15 Oct 2026 PMID 42879726
  3. Practical Pipetting Optimization Strategies for Accurate Concentration Measurement of High-Concentration Protein Formulations. AAPS PharmSciTech · 23 Sept 2026 PMID 42778828
  4. Benchmarking Automated Mass Photometry against SEC-MALS and AUC for Quantifying Cross-Linked Monoclonal Antibody Aggregates. The AAPS journal · 22 Sept 2026 PMID 42768232
  5. A hospital-based HTA model to assess the economic and organizational impact of intravenous-to-subcutaneous monoclonal antibody transitions in oncology. International journal of technology assessment in health care · 17 Sept 2026 PMID 42750487
  6. Characterization of a monoclonal antibody recognizing a conserved linear neutralizing epitope of pseudorabies virus gB protein. Archives of microbiology · 11 Sept 2026 PMID 42726283
  7. 5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study. Human vaccines & immunotherapeutics · 9 Sept 2026 PMID 42714313
  8. Comparative evaluation of screening approaches for antiviral monoclonal antibody combinations. Journal of virology · 2 Sept 2026 PMID 42684896
  9. Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. The Journal of clinical investigation · 1 Sept 2026 PMID 42677844
  10. DyAb: sequence-based antibody design and property prediction in a low-data regime. mAbs · 28 Aug 2026 PMID 42665538
  11. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. The Lancet. Oncology · 24 Aug 2026 PMID 42636836
  12. A short-course and season-oriented Stapokibart strategy for moderate-to-severe seasonal allergic rhinitis: Real-world evidence from Northern China. The World Allergy Organization journal · 20 Aug 2026 PMID 42621997
  13. Unexpected Reactivity of 1,3,4-Thiadiazole-N-oxides with Strained Alkynes Enables Enhanced Antibody Loading. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619102
  14. Development of therapeutic PD-1 monoclonal antibodies for treatment of canine tumor. Veterinary immunology and immunopathology · 11 Aug 2026 PMID 42580049
  15. Engineering High-Performance Inhalable Monoclonal Antibody Powders via Spray Freeze Drying. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 3 Aug 2026 PMID 42546983
  16. Construction of a translational whole-body physiologically based pharmacokinetic model to investigate the biodistribution of lipid nanoparticle-based mRNA therapeutics for intracellular protein targets. Journal of pharmacokinetics and pharmacodynamics · 29 Jul 2026 PMID 42527729
  17. Relaxation Processes in Freeze-Dried Monoclonal Antibody-Sucrose Formulations: The Role of Water Content. Molecular pharmaceutics · 27 Jul 2026 PMID 42504521
  18. Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. The lancet. Gastroenterology & hepatology · 16 Jul 2026 PMID 42462750
  19. Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. The lancet. Gastroenterology & hepatology · 16 Jul 2026 PMID 42462749
  20. Application of FT-IR spectroscopy as a non-invasive multi-attribute monitoring platform for critical quality attributes in monoclonal antibodies. Analytical methods : advancing methods and applications · 10 Jul 2026 PMID 42429162
  21. Thermoresponsive hydrogel for long-acting delivery of structurally intact and biologically active Fab fragment and monoclonal antibody. Acta biomaterialia · 30 Jun 2026 PMID 42379548
  22. A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy · 30 Jun 2026 PMID 42376991
  23. Development of a novel humanized monoclonal antibody and efficacy profiling of site-directed antibody-drug conjugates for precision targeted therapy of CLDN18.2-positive cancers. Bioorganic chemistry · 28 Jun 2026 PMID 42365672
  24. Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease. Inflammatory bowel diseases · 27 Jun 2026 PMID 42364076
  25. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. The New England journal of medicine · 3 Jun 2026 PMID 42234540
  26. Development of a VL domain antibody for congeneric detection of cobra (Naja spp.) venom. Toxicon : official journal of the International Society on Toxinology · 20 May 2026 PMID 42162763
  27. Monitoring disulfide scrambling of monoclonal antibody biologics using liquid chromatography-mass spectrometry coupled to online electrochemical reduction. Journal of pharmaceutical and biomedical analysis · 19 May 2026 PMID 42155371
  28. Investigation of excipient-related artifacts observed in the leachables study of tiragolumab by LC-HRMS and GC-MS. Journal of pharmaceutical and biomedical analysis · 12 May 2026 PMID 42119499

By study type

Clinical trials (4)
  1. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. The Lancet. Oncology · 24 Aug 2026 PMID 42636836
  2. Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. The lancet. Gastroenterology & hepatology · 16 Jul 2026 PMID 42462750
  3. Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. The lancet. Gastroenterology & hepatology · 16 Jul 2026 PMID 42462749
  4. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. The New England journal of medicine · 3 Jun 2026 PMID 42234540
Observational studies and case reports (1)
  1. 5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study. Human vaccines & immunotherapeutics · 9 Sept 2026 PMID 42714313
Human data, design not indexed (4)
  1. Predictors of Antiamyloid Medication Utilization and Adherence Among People With Alzheimer Disease and Mild Cognitive Impairment. Neurology · 15 Oct 2026 PMID 42879726
  2. Benchmarking Automated Mass Photometry against SEC-MALS and AUC for Quantifying Cross-Linked Monoclonal Antibody Aggregates. The AAPS journal · 22 Sept 2026 PMID 42768232
  3. A hospital-based HTA model to assess the economic and organizational impact of intravenous-to-subcutaneous monoclonal antibody transitions in oncology. International journal of technology assessment in health care · 17 Sept 2026 PMID 42750487
  4. DyAb: sequence-based antibody design and property prediction in a low-data regime. mAbs · 28 Aug 2026 PMID 42665538
Preclinical: animal, cell and lab studies (18)
  1. Monoclonal Antibody Coformulations Reveal Three Interaction Patterns Governing Stability. Molecular pharmaceutics · 2 Nov 2026 PMID 42969742
  2. Practical Pipetting Optimization Strategies for Accurate Concentration Measurement of High-Concentration Protein Formulations. AAPS PharmSciTech · 23 Sept 2026 PMID 42778828
  3. Characterization of a monoclonal antibody recognizing a conserved linear neutralizing epitope of pseudorabies virus gB protein. Archives of microbiology · 11 Sept 2026 PMID 42726283
  4. Comparative evaluation of screening approaches for antiviral monoclonal antibody combinations. Journal of virology · 2 Sept 2026 PMID 42684896
  5. Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. The Journal of clinical investigation · 1 Sept 2026 PMID 42677844
  6. Unexpected Reactivity of 1,3,4-Thiadiazole-N-oxides with Strained Alkynes Enables Enhanced Antibody Loading. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619102
  7. Development of therapeutic PD-1 monoclonal antibodies for treatment of canine tumor. Veterinary immunology and immunopathology · 11 Aug 2026 PMID 42580049
  8. Engineering High-Performance Inhalable Monoclonal Antibody Powders via Spray Freeze Drying. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 3 Aug 2026 PMID 42546983
  9. Construction of a translational whole-body physiologically based pharmacokinetic model to investigate the biodistribution of lipid nanoparticle-based mRNA therapeutics for intracellular protein targets. Journal of pharmacokinetics and pharmacodynamics · 29 Jul 2026 PMID 42527729
  10. Relaxation Processes in Freeze-Dried Monoclonal Antibody-Sucrose Formulations: The Role of Water Content. Molecular pharmaceutics · 27 Jul 2026 PMID 42504521
  11. Application of FT-IR spectroscopy as a non-invasive multi-attribute monitoring platform for critical quality attributes in monoclonal antibodies. Analytical methods : advancing methods and applications · 10 Jul 2026 PMID 42429162
  12. Thermoresponsive hydrogel for long-acting delivery of structurally intact and biologically active Fab fragment and monoclonal antibody. Acta biomaterialia · 30 Jun 2026 PMID 42379548
  13. A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy · 30 Jun 2026 PMID 42376991
  14. Development of a novel humanized monoclonal antibody and efficacy profiling of site-directed antibody-drug conjugates for precision targeted therapy of CLDN18.2-positive cancers. Bioorganic chemistry · 28 Jun 2026 PMID 42365672
  15. Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease. Inflammatory bowel diseases · 27 Jun 2026 PMID 42364076
  16. Development of a VL domain antibody for congeneric detection of cobra (Naja spp.) venom. Toxicon : official journal of the International Society on Toxinology · 20 May 2026 PMID 42162763
  17. Monitoring disulfide scrambling of monoclonal antibody biologics using liquid chromatography-mass spectrometry coupled to online electrochemical reduction. Journal of pharmaceutical and biomedical analysis · 19 May 2026 PMID 42155371
  18. Investigation of excipient-related artifacts observed in the leachables study of tiragolumab by LC-HRMS and GC-MS. Journal of pharmaceutical and biomedical analysis · 12 May 2026 PMID 42119499
Unclassified: not yet indexed with MeSH (1)
  1. A short-course and season-oriented Stapokibart strategy for moderate-to-severe seasonal allergic rhinitis: Real-world evidence from Northern China. The World Allergy Organization journal · 20 Aug 2026 PMID 42621997
bioLLM/wiki is a literature-navigation aid for people who read primary research. It is not a medical resource, and it is not a substitute for a clinician, a pharmacist or the source papers themselves. Because the articles are drafted by language models, they can be incomplete or wrong in ways that read fluently. Please see the editorial policy and medical disclaimer before relying on anything here.

Written from 28 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Last written: 2026-09-25 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.